
Paola Cipriani

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3353462/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcers. Arthritis Research, 2002, 4, R11.	2.0	230
2	Angiogenesis in rheumatoid arthritis: A disease specific process or a common response to chronic inflammation?. Autoimmunity Reviews, 2011, 10, 595-598.	2.5	168
3	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmunity Reviews, 2012, 12, 225-229.	2.5	146
4	The Role of IL-1 <i>β</i> in the Bone Loss during Rheumatic Diseases. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	146
5	Efficacy and safety of rituximab treatment in early primary SjĶgren's syndrome: a prospective, multi-center, follow-up study. Arthritis Research and Therapy, 2013, 15, R172.	1.6	143
6	Impairment of endothelial cell differentiation from bone marrow–derived mesenchymal stem cells: New insight into the pathogenesis of systemic sclerosis. Arthritis and Rheumatism, 2007, 56, 1994-2004.	6.7	138
7	Beyond the joints, the extra-articular manifestations in rheumatoid arthritis. Autoimmunity Reviews, 2021, 20, 102735.	2.5	135
8	Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers. BMC Medicine, 2016, 14, 194.	2.3	130
9	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides,) Tj ETQq1 1 0.78	4314 rgBT 2.5	- Overlock 107
10	Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis. Autoimmunity Reviews, 2019, 18, 93-106.	2.5	101
11	Methotrexate: an old new drug in autoimmune disease. Expert Review of Clinical Immunology, 2014, 10, 1519-1530.	1.3	100
12	Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1 î² via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. Clinical and Experimental Immunology, 2015, 182, 35-44.	1.1	100
13	The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 598-605.	0.5	97
14	Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Medicine, 2019, 16, e1002901.	3.9	94
15	Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis. Journal of Rheumatology, 2002, 29, 731-6.	1.0	93
16	Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Frontiers in Pharmacology, 2017, 8, 369.	1.6	89
17	Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmunity Reviews, 2011, 10, 590-594.	2.5	88
18	Longterm Retention of Tumor Necrosis Factor-α Inhibitor Therapy in a Large Italian Cohort of Patients with Rheumatoid Arthritis from the GISEA Registry: An Appraisal of Predictors. Journal of Rheumatology, 2012, 39, 1179-1184.	1.0	87

#	Article	IF	CITATIONS
19	Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clinical Rheumatology, 2014, 33, 49-55.	1.0	84
20	Immunomodulation in psoriatic arthritis: Focus on cellular and molecular pathways. Autoimmunity Reviews, 2013, 12, 599-606.	2.5	83
21	The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. Journal of Rheumatology, 2015, 42, 1808-1816.	1.0	82
22	Interleukinâ€9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis. Arthritis and Rheumatology, 2016, 68, 1922-1931.	2.9	80
23	Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. Frontiers in Immunology, 2020, 11, 1130.	2.2	79
24	Interstitial lung disease in systemic sclerosis: current and future treatment. Rheumatology International, 2017, 37, 853-863.	1.5	76
25	Computed Tomography and MR Imaging in Rheumatoid Arthritis. Radiologic Clinics of North America, 2017, 55, 997-1007.	0.9	74
26	Macrophage Activation Syndrome in Patients Affected by Adult-onset Still Disease: Analysis of Survival Rates and Predictive Factors in the Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale Cohort. Journal of Rheumatology, 2018, 45, 864-872.	1.0	70
27	Early assessment of sub-clinical cardiac involvement in systemic sclerosis (SSc) using delayed enhancement cardiac magnetic resonance (CE-MRI). European Journal of Radiology, 2013, 82, e268-e273.	1.2	66
28	Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers. Autoimmunity Reviews, 2017, 16, 16-21.	2.5	65
29	Differential expression of stromal cell–derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis and Rheumatism, 2006, 54, 3022-3033.	6.7	64
30	A retrospective, multicenter study evaluating the prognostic value of minor salivary gland histology in a large cohort of patients with primary SjA¶gren's syndrome. Lupus, 2015, 24, 315-320.	0.8	63
31	Methotrexate in Rheumatoid Arthritis: Optimizing Therapy Among Different Formulations. Current and Emerging Paradigms. Clinical Therapeutics, 2014, 36, 427-435.	1.1	62
32	Scleroderma Mesenchymal Stem Cells display a different phenotype from healthy controls; implications for regenerative medicine. Angiogenesis, 2013, 16, 595-607.	3.7	61
33	Is minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren׳s syndrome? Association between clinical, histopathological, and molecular features: A retrospective study. Seminars in Arthritis and Rheumatism, 2014, 44, 314-324.	1.6	61
34	CD4â^'CD8â^' T-cells in primary Sjögren's syndrome: Association with the extent of glandular involvement. Journal of Autoimmunity, 2014, 51, 38-43.	3.0	60
35	Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. Clinical and Experimental Immunology, 2013, 173, 195-206.	1.1	59
36	T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	59

#	Article	IF	CITATIONS
37	Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. Clinical Rheumatology, 2017, 36, 2839-2845.	1.0	53
38	Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmunity Reviews, 2011, 10, 641-646.	2.5	52
39	Stem cells in autoimmune diseases: Implications for pathogenesis and future trends in therapy. Autoimmunity Reviews, 2013, 12, 709-716.	2.5	51
40	Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. Arthritis Research and Therapy, 2014, 16, 442.	1.6	49
41	Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. Autoimmunity Reviews, 2015, 14, 429-437.	2.5	46
42	IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone?. Expert Review of Clinical Immunology, 2016, 12, 849-855.	1.3	46
43	PTP4A1 promotes TGFÎ ² signaling and fibrosis in systemic sclerosis. Nature Communications, 2017, 8, 1060.	5.8	46
44	Perivascular Cells in Diffuse Cutaneous Systemic Sclerosis Overexpress Activated ADAM12 and Are Involved in Myofibroblast Transdifferentiation and Development of Fibrosis. Journal of Rheumatology, 2016, 43, 1340-1349.	1.0	45
45	Surface Expression of Fractalkine Receptor (CX3CR1) on CD4+/CD28 T Cells in RA Patients and Correlation with Atherosclerotic Damage. Annals of the New York Academy of Sciences, 2007, 1107, 32-41.	1.8	43
46	Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis. Medicine (United States), 2017, 96, e7896.	0.4	42
47	Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. Expert Review of Clinical Immunology, 2017, 13, 1089-1097.	1.3	42
48	Poor clinical response in rheumatoid arthritis is the main risk factor for diabetes development in the short-term: A 1-year, single-centre, longitudinal study. PLoS ONE, 2017, 12, e0181203.	1.1	42
49	A genetic variation located in the promoter region of the <i>UPAR</i> (<i>CD87</i>) gene is associated with the vascular complications of systemic sclerosis. Arthritis and Rheumatism, 2011, 63, 247-256.	6.7	41
50	Rituximab modulates IL-17 expression in the salivary glands of patients with primary Sjögren's syndrome. Rheumatology, 2014, 53, 1313-1320.	0.9	41
51	Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS ONE, 2017, 12, e0170108.	1.1	41
52	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Arthritis Research and Therapy, 2019, 21, 204.	1.6	40
53	Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. Clinical and Experimental Immunology, 2015, 181, 219-229.	1.1	38
54	Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations. Scientific Reports, 2020, 10, 12232.	1.6	38

#	Article	IF	CITATIONS
55	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity—characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients. Arthritis Research and Therapy, 2020, 22, 151.	1.6	38
56	The growing role of precision medicine for the treatment of autoimmune diseases; results of a systematic review of literature and Experts' Consensus. Autoimmunity Reviews, 2021, 20, 102738.	2.5	38
57	Unmasking the pathogenic role of IL-17 axis in primary Sjögren's syndrome: A new era for therapeutic targeting?. Autoimmunity Reviews, 2014, 13, 1167-1173.	2.5	36
58	Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets?. Expert Review of Clinical Immunology, 2017, 13, 1041-1047.	1.3	36
59	IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes. Medicine (United States), 2019, 98, e14587.	0.4	36
60	Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander?. Annals of the Rheumatic Diseases, 2020, 79, 1515-1516.	0.5	36
61	Serum levels of soluble CD30 are increased in ulcerative colitis (UC) but not in Crohn's disease (CD). Clinical and Experimental Immunology, 1998, 111, 532-535.	1.1	35
62	Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma). Annals of the Rheumatic Diseases, 2001, 60, 487-494.	0.5	35
63	Long-Term Retention Rate of Anakinra in Adult Onset Still's Disease and Predictive Factors for Treatment Response. Frontiers in Pharmacology, 2019, 10, 296.	1.6	35
64	The â^'670G>A polymorphism in the <i>FAS</i> gene promoter region influences the susceptibility to systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 584-590.	0.5	34
65	Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary SJŶgren's syndrome: a pilot study. Clinical and Experimental Immunology, 2016, 184, 284-292.	1.1	32
66	Safety and efficacy of intra-articular anti-tumor necrosis factor α agents compared to corticosteroids in a treat-to-target strategy in patients with inflammatory arthritis and monoarthritis flare. International Journal of Immunopathology and Pharmacology, 2016, 29, 252-266.	1.0	32
67	Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?. Autoimmunity Reviews, 2015, 14, 575-578.	2.5	31
68	Phenotypical and Functional Characteristics of in Vitro-Expanded Adipose-Derived Mesenchymal Stromal Cells from Patients with Systematic Sclerosis. Cell Transplantation, 2017, 26, 841-854.	1.2	31
69	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of theÂmulticentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort. PLoS ONE, 2020, 15, e0235326.	1.1	31
70	Association between a stromal cell-derived factor 1 (<i>SDF-1/CXCL12</i>) gene polymorphism and microvascular disease in systemic sclerosis. Annals of the Rheumatic Diseases, 2009, 68, 408-411.	0.5	29
71	Rituximab modulates the expression of IL-22 in the salivary glands of patients with primary Sjogren's syndrome. Annals of the Rheumatic Diseases, 2013, 72, 782-783.	0.5	29
72	Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: a new potential target for antifibrotic therapy. Arthritis Research and Therapy, 2018, 20, 223.	1.6	29

#	Article	IF	CITATIONS
73	Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. Journal of Medical Case Reports, 2015, 9, 123.	0.4	28
74	Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study. Medicine (United) Tj ETQqC	0 0 rgB4 /0v	verl øz k 10 Tf 5

75	Myositis in primary Sjögren's syndrome: data from a multicentre cohort. Clinical and Experimental Rheumatology, 2015, 33, 457-64.	0.4	27
76	Scleroderma fibroblasts suppress angiogenesis via TGF-β/caveolin-1 dependent secretion of pigment epithelium-derived factor. Annals of the Rheumatic Diseases, 2018, 77, 431-440.	0.5	26
77	Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis. Arthritis Research and Therapy, 2021, 23, 213.	1.6	25
78	Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis. Fibrogenesis and Tissue Repair, 2014, 7, 13.	3.4	24
79	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. Rheumatology, 2021, 60, 4844-4849.	0.9	23
80	Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts. Arthritis Research and Therapy, 2015, 17, 247.	1.6	22
81	Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clinical Rheumatology, 2017, 36, 251-260.	1.0	22
82	Mortality in tocilizumab-treated patients with COVID-19: a systematic review and meta-analysis. Clinical and Experimental Rheumatology, 2020, 38, 1247-1254.	0.4	22
83	The Effect of Ketogenic Diet on Inflammatory Arthritis and Cardiovascular Health in Rheumatic Conditions: A Mini Review. Frontiers in Medicine, 2021, 8, 792846.	1.2	22
84	The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. Modern Rheumatology, 2018, 28, 922-932.	0.9	21
85	Comparison of Early vs. Delayed Anakinra Treatment in Patients With Adult Onset Still's Disease and Effect on Clinical and Laboratory Outcomes. Frontiers in Medicine, 2020, 7, 42.	1.2	21
86	Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities. Journal of Immunology Research, 2018, 2018, 1-10.	0.9	20
87	Downregulation of miRNA17–92 cluster marks Vγ9VÎ′2 T cells from patients with rheumatoid arthritis. Arthritis Research and Therapy, 2018, 20, 236.	1.6	20
88	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life―cohort. Rheumatology International, 2020, 40, 107-113.	1.5	20
89	Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. Cytotherapy, 2015, 17, 832-849.	0.3	19
90	Variations of neuronal nitric oxide synthase in systemic sclerosis skin. Arthritis and Rheumatism, 2006, 54, 202-213.	6.7	18

#	Article	IF	CITATIONS
91	Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. Expert Review of Clinical Immunology, 2013, 9, 441-452.	1.3	18
92	Interleukinâ€25 Axis Is Involved in the Pathogenesis of Human Primary and Experimental Murine Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 1265-1275.	2.9	18
93	Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling. Scientific Reports, 2019, 9, 7144.	1.6	18
94	Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension. Arthritis Research and Therapy, 2020, 22, 127.	1.6	18
95	Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic sclerosis patients of recent onset. International Journal of Rheumatic Diseases, 2017, 20, 1247-1260.	0.9	15
96	Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis. Journal of Rheumatology, 2006, 33, 2003-14.	1.0	15
97	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Ophthalmology and Therapy, 2022, 11, 899-911.	1.0	14
98	Endothelial progenitor cells: Are they displaying a function in autoimmune disorders?. Mechanisms of Ageing and Development, 2016, 159, 44-48.	2.2	13
99	Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy. Expert Review of Clinical Pharmacology, 2020, 13, 593-604.	1.3	13
100	Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts. Scientific Reports, 2019, 9, 4589.	1.6	12
101	The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection. Expert Review of Clinical Immunology, 2020, 16, 1205-1215.	1.3	12
102	Expanding the spectrum of the hyperferritinemic syndrome, from pathogenic mechanisms to clinical observations, and therapeutic implications. Autoimmunity Reviews, 2022, 21, 103114.	2.5	12
103	Stem cell therapies for systemic sclerosis. British Journal of Haematology, 2015, 168, 328-337.	1.2	11
104	Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sj¶gren's syndrome minor salivary glands. PLoS ONE, 2019, 14, e0211142.	1.1	11
105	Hepatitis E Virus and rheumatic diseases: what do rheumatologists need to know?. BMC Rheumatology, 2020, 4, 51.	0.6	10
106	The joint involvement in adult onset Still's disease is characterised by a peculiar magnetic resonance imaging and a specific transcriptomic profile. Scientific Reports, 2021, 11, 12455.	1.6	10
107	Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review). Molecular Medicine Reports, 2019, 20, 1488-1498.	1.1	10
108	The Vessels Contribute to Fibrosis in Systemic Sclerosis. Israel Medical Association Journal, 2019, 21, 471-474.	0.1	10

#	Article	IF	CITATIONS
109	The clinical heterogeneity of adult onset Still's disease may underlie different pathogenic mechanisms. Implications for a personalised therapeutic management of these patients. Seminars in Immunology, 2021, 58, 101632.	2.7	10
110	The kaleidoscope of neurological manifestations in primary Sjögren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 192-198.	0.4	9
111	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9
112	Searching for a good model for systemic sclerosis: the molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis. Archives of Medical Science, 2016, 4, 828-843.	0.4	7
113	Pathogenic implications, incidence, and outcomes of COVID-19 in autoimmune inflammatory joint diseases and autoinflammatory disorders. Advances in Rheumatology, 2021, 61, 45.	0.8	7
114	Systemic syndromes of rheumatological interest with onset after COVID-19 vaccine administration: a report of 30 cases. Clinical Rheumatology, 2022, 41, 2261-2267.	1.0	7
115	Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-12 and IL-6. Pharmaceuticals, 2022, 15, 622.	1.7	7
116	Hepatitis E infection in a patient with rheumatoid arthritis treated with leflunomide. Medicine (United) Tj ETQq0 (0 0 rgBT /0	Overlock 10 ⁻
117	Association Between Minor Salivary Gland Biopsy During Sjӧgren's Syndrome and Serologic Biomarkers: A Systematic Review and Meta-Analysis. Frontiers in Immunology, 2021, 12, 686457.	2.2	6
118	Laboratory Assessment of Patients with Suspected Rheumatic Musculoskeletal Diseases: Challenges and Pitfalls. Current Rheumatology Reviews, 2018, 15, 27-43.	0.4	6
119	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. Clinical Rheumatology, 2022, 41, 641-647.	1.0	6
120	Vitamin D increases the production of IL-10 by regulatory T cells in patients with systemic sclerosis. Clinical and Experimental Rheumatology, 2019, 37 Suppl 119, 76-81.	0.4	6
121	Safety and efficacy of certolizumab pegol in a real-life cohort of patients with psoriasis and psoriatic arthritis. Journal of Dermatological Treatment, 2020, 31, 692-697.	1.1	5
122	Haematopoietic stem cell transplantation in systemic sclerosis: Challenges and perspectives. Autoimmunity Reviews, 2020, 19, 102662.	2.5	5
123	Evaluating the multivisceral involvement on adult-onset Still's disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study. Clinical Rheumatology, 2021, 40, 3971-3978.	1.0	5
124	Persistence of focal lymphocytic sialadenitis in patients with primary Sjögren's syndrome treated with rituximab: a possible role for glandular BAFF. Clinical and Experimental Rheumatology, 2016, 34, 1123-1124.	0.4	4
125	Use of Rituximab in the Management of Sjögren's Syndrome. Current Treatment Options in Rheumatology, 2015, 1, 277-291.	0.6	3

Adipose stromal vascular fraction and regenerative therapy in SSc: response to the article by Magalon et al. Annals of the Rheumatic Diseases, 2020, 79, e53-e53.

0

#	Article	IF	CITATIONS
127	Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis. Scientific Reports, 2022, 12, 5125.	1.6	3
128	Advanced diagnostic imaging and intervention in tendon diseases. Acta Biomedica, 2020, 91, 98-106.	0.2	2
129	Novel biomarker for pulmonary vascular disease in systemic sclerosis patients. Clinical and Experimental Rheumatology, 2022, , .	0.4	2
130	Mesenchymal Stem Cell Transplantation in Systemic Sclerosis: Comment on the Article by Maria et al. Arthritis and Rheumatology, 2016, 68, 2348-2348.	2.9	1
131	Tailored approach to rheumatoid arthritis treatment with TNF inhibitors: where do we stand?. Rheumatology, 2018, 57, vii1-vii4.	0.9	1
132	Response to: â€~Correspondence on â€~Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences' by Ruscitti <i>et al</i> ' by Chen <i>et al</i> . Annals of the Rheumatic Diseases, 2022, 81, e221-e221.	0.5	1
133	Correspondence on †Disease activity, cytokines, chemokines and the risk of incident diabetes in rheumatoid arthritis'. Annals of the Rheumatic Diseases, 2023, 82, e119-e119.	0.5	1
134	Long-term safety of rituximab in primary Sjögren's syndrome: the experience of a single centre. Journal of Rheumatology, 2021, , jrheum.210441.	1.0	1
135	Potential of stem cells in the treatment of rheumatic disease. International Journal of Clinical Rheumatology, 2014, 9, 183-195.	0.3	0
136	Erratum to "ls minor salivary gland biopsy more than a diagnostic tool in primary Sjo¨gren's syndrome? Association between clinical, histopathological, and molecular features: A retrospective study―[Semin Arthritis Rheum 44 (2014) 314–324]. Seminars in Arthritis and Rheumatism, 2015, 44, e23.	1.6	0
137	Comment on â€Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?'. Autoimmunity Reviews, 2016, 15, 202.	2.5	0
138	Duration of clinical remission and low disease activity impacts on quality of life and its domains in psoriatic arthritis patients: results from an Italian multicentre study. Clinical and Experimental Rheumatology, 2021, , .	0.4	0
139	Title is missing!. , 2020, 15, e0235326.		0
140	Title is missing!. , 2020, 15, e0235326.		0
141	Title is missing!. , 2020, 15, e0235326.		0

142 Title is missing!. , 2020, 15, e0235326.